[Clinical manifestations of Legionella pneumonia in hematology patients].
OBJECTIVE
To detect the most common clinical manifestations of Legionella pneumonia (LP) in immunocompromized patients.


METHODS
Clinical manifestations, the results of investigation of bronchoalveolar lavage fluid (BALF) and urine, and the data of lung computed tomography (CT) were studied in patients with blood system diseases and acute respiratory failure (ARF).


RESULTS
The diagnosis of LP was verified in 8 (10.5%) of 76 patients with blood system diseases and ARF. The disease manifested as fever, higher concentrations of inflammatory markers (procalcitonin, fibrinogen), ARF, hypoxemia, and infiltrative lung injury. Six of the 8 patients were switched to mechanical ventilation. Lung CT showed no pathognomonic signs. Five of the 8 patients were observed to have renal dysfunction. The diagnosis of LP was made on the basis of the results of BALF examination in 7 patients and urinary antigen detection in 1. The disease was caused by Legionella pneumophila serogroup 1 in 3 patients and by L. pneumophila of other serogroups in the other patients. Therapy with respiratory fluoroquinolones was performed in 5 patients. Three patients died from progressive ARF and hypoxemia. BALF results were obtained after their death and therapy for legionellosis was not initiated.


CONCLUSIONS
The incidence of LP is 10.5% in hematology patients. The clinical manifestations of legionellosis are nonspecific; its diagnosis requires bacteriological and/or serological evidence. Due to the high risk of death, it is reasonable to preuse respiratory fluoroquinolones or macrolides in immunocompromized patients with progressive ARF and suspected Legionella pneumonia before diagnosis.
G M
GM
Galstian
I É
IÉ
Kostina
S A
SA
Katrysh
G A
GA
Kliasova
T I
TI
Karpova
I S
IS
Tartakovskiĭ
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000942:Antigens, Bacterial / Q000652:urine; D018893:Bronchoalveolar Lavage / Q000379:methods; D005260:Female; D024841:Fluoroquinolones / Q000627:therapeutic use*; D006402:Hematologic Diseases / Q000150:complications / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D007875:Legionella / Q000276:immunology; D007877:Legionnaires' Disease / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000276:immunology / Q000503:physiopathology; D018942:Macrolides / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D012131:Respiratory Insufficiency / Q000188:drug therapy / Q000209:etiology / Q000401:mortality / Q000503:physiopathology; D012426:Russia / Q000453:epidemiology; D015996:Survival Rate; D014057:Tomography, X-Ray Computed / Q000379:methods
D000900:Anti-Bacterial Agents; D000942:Antigens, Bacterial; D024841:Fluoroquinolones; D018942:Macrolides